Cardiac Marker Testing Market by Product (Instruments, Reagents & Kits), Biomarker (BNP Or NT-ProBNP, Ceratine Kinase-MB, hs-CRP), Type of Testing, Disease - Global Forecast 2024-2030

[196 Pages Report] The Cardiac Marker Testing Market size was estimated at USD 5.10 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 7.90% to reach USD 8.69 billion by 2030.

Cardiac marker testing market consists of the spectrum of medical technologies and services that revolve around the usage of biomarkers for the diagnosis and management of cardiovascular diseases. The prevalence of cardiovascular diseases and need for effective diagnostics has increased the adoption of cardiac markers worldwide. The rise of point-of-care testing for cardiac markers has significantly increased the screening of cardiovascular diseases. The initiatives encouraging early cardiovascular disease detection have also contributed to market growth. However, the incidences of product recalls of cardiac marker testing solutions may limit its market adoption. The concerns associated with inaccuracy and limited specificity of cardiac market testing are also challenging factors for the market growth. Moreover, the advancements in testing technologies and the integration of new biomarkers are creating attractive opportunities in the market. Increasing consumer preference towards personalized medicine and the introduction of tailored cardiac marker testing are expected to witness significant growth in upcoming years.

In the Americas region, the cardiac marker testing market has been flourishing with advancements in technology and the escalating prevalence of cardiovascular diseases. Several local companies and start-ups in major countries such as the United States, Canada, and Brazil, have been focusing on developing and introducing cost-effective and portable devices for effective cardiac assessment. In the Europe region, the cardiac marker testing market has been extensively driven by the increasing number of cardiovascular diseases, the aging population, and the well-established healthcare infrastructure. The cardiac marker testing market in the Middle East and Africa has been significantly impacted due to the rising awareness about coronary people diseases and the expansion of healthcare services. Cardiac marker testing market has been growing at an accelerated rate in APAC countries including China, India, and Japan due to the surge in healthcare services and the significant presence of major companies. The government support in terms of investments for healthcare research and development has led to an increase in innovations in cardiac testing methods.

The market dynamics represent an ever-changing landscape of the Cardiac Marker Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Prevalence of cardiovascular diseases and need for effective diagnostics
  • Rise of point-of-care testing for cardiac markers worldwide
  • Initiatives encouraging early detection and screening of cardiovascular diseases
• Market Restraints
  • Adverse recalls of cardiac marker testing products
• Market Opportunities
  • Advancements in testing technologies and integration of new biomarkers
  • Shift toward personalized medicine and introduction of tailored cardiac marker testing
• Market Challenges
  • Concerns associated with inaccuracy and limited specificity of cardiac marker testing

• Product: Significance of diagnostic instruments in cardiac marker testing

  Diagnostic instruments in cardiac marker testing includes immunoassay analyzers, point of care (POC) devices, and chemiluminescence analyzers utilized to monitor and measure cardiac markers corresponding to heart conditions. Diagnostic instruments offer essential data evaluation for cardiac tests in a highly accurate, timely, and user-friendly manner. Reagents & kits are chemical solutions used for the proper functioning of instruments and the successful execution of cardiac marker testing procedures. Reagents & kits are vital in reacting with the biological samples, thereby helping to detect cardiac markers for various cardiac conditions.

• Biomarker: Rising utilization of Troponin biomarker for cardiac assessment

  Natriuretic peptides such as N-terminal proBNP (NT-proBNP) and B-type Natriuretic Peptide (BNP) are essential in the evaluation of heart failure, helping clinicians on cardiac disease management. Though CK-MB, a Creatine Kinase-MB isoenzyme, has been used in periprocedural myocardial infarction testings to better diagnose cardiac condition. High-sensitivity C-reactive protein (hs-CRP) testing is particularly advantageous for identifying low-grade inflammation to assess the risk of cardiovascular disease and stroke. Myoglobin is also a significant cardiac biomarker, favored for its very early peak (1 to 3 hours) following myocardial injury, primarily beneficial in the early detection of myocardial infarction. Troponin tests are currently the standard of care for diagnosing acute myocardial infarction due to their superior sensitivity and specificity.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiac Marker Testing Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Marker Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Marker Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays

  Mindray, a provider of medical devices and solutions, launched two advanced cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP, for diagnosing and managing cardiovascular diseases (CVDs). The NT-proBNP assay demonstrates exceptional precision, with a coefficient of variation (CV) of less than or equal to 5%. Furthermore, it eliminates interference from 55 medications commonly used to treat heart diseases. This makes it a highly reliable tool for detecting and managing heart failure. Mindray's commitment to innovation in cardiac marker testing ensures accurate and efficient diagnosis and management of CVDs. [Published On: October 23, 2023]

• NOWDx and AeenaDx Announce Merger

  NOWDx and AeenaDx have merged to form NOWDiagnostics (NOWDx). NOWDx is strategically positioned to cater to the global point of care (POC) and over-the-counter (OTC) diagnostics market. The main areas of focus for NOWDx include the commercialization of tests for Syphilis and Strep, as well as ongoing development for infectious diseases, women's health, drugs of abuse, cardiac markers, and cancer. The company is committed to delivering accurate and reliable diagnostic solutions to healthcare providers and patients worldwide. [Published On: April 28, 2023]

• Pathkind Labs, Roche Diagnostics Partner to Release Cardiac Biomarker

  Pathkind Labs and Roche Diagnostics are partnered to introduce NTProBNP, a cardiac marker used for detecting heart failure in patients. Research conducted by the Trivandrum Heart-Failure Registry demonstrates that T2DM is a common comorbidity among hospitalized patients, accounting for 55 percent of cases. This marker is crucial in managing Type 2 Diabetes (T2DM) while re-evaluating the patient's treatment. [Published On: January 06, 2023]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Marker Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Cardiac Marker Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Assure Tech (Hangzhou) Co., Ltd., Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biomérieux SA, Boditech Med Inc., Charles River Laboratories International, Inc., Cleerly, Inc., Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche AG, HyTest Ltd., Laboratory Corporation of America Holdings, LightDeck Diagnostics, Merck KGaA, Natera, Inc., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics, QuidelOrtho Corporation, Randox Laboratories Ltd., Sekbio, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

This research report categorizes the Cardiac Marker Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Instruments
    • Chemiluminescence
    • ELISA
    • Immunochromatography
    • Immunofluorescence
  • Reagents & Kits
• Biomarker
  • BNP Or NT-ProBNP
  • Ceratine Kinase-MB
  • hs-CRP
  • Myoglobin
  • Troponin
• Type of Testing
  • Laboratory Testing
  • Point-Of-Care Testing
• Disease
  • Congestive Heart Failure
  • Myocardial Infarction

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?